Diabetic Kidney Disease: From Mechanisms to Treatment
October 24, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
Oral Abstract Session
Diabetic Kidney Disease: From Mechanisms to Treatment
October 24, 2020 | 05:00 PM - 07:00 PM
Location: Simulive
Session Description
Oral Abstract Session
Learning Pathway(s)
Moderators
- Alessia Fornoni, MD, PhD, FASN
- Monika A. Niewczas, MD, PhD, MPH
Presentations
- p53/MicroRNA-214/ULK1 Axis Impairs Renal Tubular Autophagy in Diabetic Kidney Disease
05:00 PM - 07:00 PM
Zhengwei Ma, PhD
p53/MicroRNA-214/ULK1 Axis Impairs Renal Tubular Autophagy in Diabetic Kidney Disease
October 24, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Podocytes-Derived Extracellular Vesicles Mediate Renal Proximal Tubule Cells Dedifferentiation via MicroRNA 221 in Diabetic Nephropathy
05:00 PM - 07:00 PM
Hong Su
Hong Su
Hong Su, comes from China, is a student from Department of Nephrology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University.
Podocytes-Derived Extracellular Vesicles Mediate Renal Proximal Tubule Cells Dedifferentiation via MicroRNA 221 in Diabetic Nephropathy
October 24, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Whole-Genome Sequencing Identifies a Dominant Negative ADIPOQ Mutation in a Type 2 Diabetic Family Enriched for ESRD
05:00 PM - 07:00 PM
Marcus G. Pezzolesi, PhD, MPH
Marcus G. Pezzolesi, PhD, MPH
Whole-Genome Sequencing Identifies a Dominant Negative ADIPOQ Mutation in a Type 2 Diabetic Family Enriched for ESRD
October 24, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Enhancing Kidney DDAH-1 Expression by Adenovirus Delivery Reduces Asymmetric Dimethylarginine and Ameliorates Diabetic Nephropathy
05:00 PM - 07:00 PM
Michael Wetzel, PhD
Michael Wetzel, PhD
Michael Wetzel, Ph.D is currently a postdoctoral fellow in Dr. Alaa Awad’s lab at UT Health-San Antonio. Dr. Wetzel obtained his BS from Texas A&M University, MS from UT Health-San Antonio, and PhD in cell biology from University of Texas Medical Branch. He came to Dr. Awad’s lab in 2018, which focuses on diabetic kidney disease. Dr. Wetzel’s current work involves the role of arginine and nitric oxide interaction in diabetic kidney disease. This presentation for 2020 ASN is titled “Enhancing Kidney DDAH-1 Expression by Adenovirus Delivery Reduces ADMA and Ameliorates Diabetic Nephropathy”.
Enhancing Kidney DDAH-1 Expression by Adenovirus Delivery Reduces Asymmetric Dimethylarginine and Ameliorates Diabetic Nephropathy
October 24, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Cell Type Specificity of Hypoxia Signaling in Early Diabetic Kidney Disease (DKD)
05:00 PM - 07:00 PM
Jennifer A. Schaub, MD
Cell Type Specificity of Hypoxia Signaling in Early Diabetic Kidney Disease (DKD)
October 24, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Loss of Functional SCO2 Attenuates Diabetic Kidney Disease in db/db Mice
05:00 PM - 07:00 PM
Nehaben A. Gujarati, PhD
Nehaben A. Gujarati, PhD
Nehaben A. Gujarati completed her Bachelor’s in Pharmacy from India and earned her Master’s and Ph.D. at St. John’s University, New York. She is currently doing her postdoctoral with Dr. Sandeep K. Mallipattu in the division of Nephrology at Stony brook University-School of Medicine. Her research is mainly focused on understanding the role of mitochondria in diabetic kidney disease
Loss of Functional SCO2 Attenuates Diabetic Kidney Disease in db/db Mice
October 24, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Reversal of Diabetic Nephropathy After 10 Years of Pancreas Transplantation Occurs Despite Parallel Podocyte Loss
05:00 PM - 07:00 PM
Behzad Najafian, MD
Reversal of Diabetic Nephropathy After 10 Years of Pancreas Transplantation Occurs Despite Parallel Podocyte Loss
October 24, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Urinary Proteomics Identifies Proteins Associated with Rapid eGFR Decline in Type 1 Diabetes
05:00 PM - 07:00 PM
Christine P. Limonte, MD
Christine P. Limonte, MD
Christine Limonte is a Nephrology Clinical Research Fellow at the University of Washington. Her research interests include diabetic kidney disease pathophysiology and the mechanisms underlying various phenotypes of diabetic kidney disease.
Urinary Proteomics Identifies Proteins Associated with Rapid eGFR Decline in Type 1 Diabetes
October 24, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6
05:00 PM - 07:00 PM
Katherine R. Tuttle, MD, FASN
Katherine R. Tuttle, MD, FASN
Katherine R. Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Health Care, Co-Principal Investigator of the Institute of Translational Health Sciences and Professor of Medicine at the University of Washington. Dr. Tuttle earned her medical degree and completed her residency in Internal Medicine at Northwestern University School of Medicine in Chicago, Illinois. She was a fellow in Metabolism and Endocrinology at Washington University in St. Louis, Missouri. Her Nephrology fellowship training was performed at University of Texas Health Science Center in San Antonio, Texas.
Dr. Tuttle’s major research interests are in clinical and translational science for diabetes and chronic kidney disease. She has published over 200 original research contributions and served two terms as Associate Editor for the Clinical Journal of the American Society of Nephrology and the American Journal of Kidney Disease. Dr. Tuttle has received many honors and awards including the Medal of Excellence from the American Association of Kidney Patients, Garbed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two Outstanding Clinical Faculty Awards at the University of Washington. Dr. Tuttle served on the Board of Directors for the Kidney Health Initiative and has chaired numerous kidney and diabetes related working groups and committees for organizations including the NIDDK/NIH, the National Kidney Foundation, the American Society of Nephrology, the International Society of Nephrology, and the American Diabetes Association.
Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6
October 24, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes
05:00 PM - 07:00 PM
Rajiv Agarwal, MD, MS, FASN
Rajiv Agarwal, MD, MS, FASN
Dr. Rajiv Agarwal is a practicing nephrologist and a tenured Professor of Medicine at Indiana University School of Medicine at Indianapolis, IN. Dr. Agarwal earned his medical degree from the All India Institute of Medical Sciences in New Delhi. After completing residency in Internal Medicine at the same institution he completed a Nephrology fellowship at University of Texas, Southwestern Dallas. Dr. Agarwal has published > 300 original papers and reviews in Nephrology. He has had numerous invited lectures including those from national societies such as National Kidney Foundation, American Society Nephrology, International Society of Nephrology, European Dialysis and Transplant Association, and the American Heart Association. Dr. Agarwal has received the Indiana University Trustee’s teaching award and the young scholar award of the American Society of Hypertension. He serves or has served on the Editorial Boards of numerous journals such as Kidney International, CJASN, Hypertension and Seminars in Dialysis and he is currently an Editor for Nephrology Dialysis Transplantation, and the American Journal of Nephrology. In the past he served as an editor for the Journal of the American Society of Hypertension and NephSAP.
Dr. Agarwal is an internationally recognized leader in the area of clinical and translational research in nephrology. His foremost contribution has been in the area of hypertension in hemodialysis patients for which he has been funded continuously since 2003 by the National Institutes of Health. He has refined the techniques to diagnose and treat hypertension in this complex group of patients and performed important randomized trials in this difficult group of patients. He serves on the Board of Directors of KDIGO, has served as a panelist for Medical Evidence Development Coverage Advisory Committee (MEDCAC) for United States Medicare, co-edited a textbook of hypertension in chronic kidney disease and is a recipient of the Clinical Excellence award from the American Nephrologists of Indian Origin (ANIO). He has chaired several kidney event adjudication committees for large randomized clinical trials including CREDENCE, SONAR, BEACON, FIGARO, and FIDELIO and currently serves as the chair of a core group lead by the International Society of Nephrology (ISN) to standardize the definitions of kidney failure for use in clinical trials worldwide.
Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes
October 24, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
